Browse result page of CancerPDF Database

Please click on CancerPDF_ID for detailed information about peptide.

CancerPDF_IDPeptide seqProtein NameFluidMass/ZProfiling TechniqueCancer Type Expression RegulationPUBMED ID
CancerPDF_ID998 NANASerum6635.24MALDI-TOFColorectal cancer Downregulated in cancer vs normal 23091368
CancerPDF_ID1177 NANASerum6047.99MALDI-TOFLung cancer Upregulated in cancer vs normal with average expression of peptide in cancer 1.3 and in normal 0.86 21082738
CancerPDF_ID1178 NANASerum6938.61MALDI-TOFLung cancer Downregulated in cancer vs normal with average expression of peptide in cancer 0.55 and in normal 0.74 21082738
CancerPDF_ID1184 NANASerum6431.8MALDI-TOFLung cancer Downregulated in cancer vs normal with average expression of peptide in cancer 2.31 and in normal 4.32 21082738
CancerPDF_ID1185 NANASerum6389.3MALDI-TOFLung cancer Downregulated in cancer vs normal with average expression of peptide in cancer 0.61 and in normal 0.98 21082738
CancerPDF_ID3265 NAApolipoprotein C-ISerum6431MALDI-TOFStomach adenocarcinoma Differentially expressed in cancer patients as cpmpare to normal 21267442
CancerPDF_ID3266 NAApolipoprotein C-ISerum6629MALDI-TOFStomach adenocarcinoma Differentially expressed in cancer patients as cpmpare to normal 21267442
CancerPDF_ID3275 NANASerum6636MALDI-TOFOvarian cancer Differentially expressed between normal and patients 22086897
CancerPDF_ID3291 NANASerum6437.3MALDI-TOFOvarian cancer Differentially expressed between normal and patients 22086897
CancerPDF_ID3320 NANASerum6385.4MALDI-TOFOvarian cancer Differentially expressed between normal and patients 22086897
CancerPDF_ID3324 NANASerum6810MALDI-TOFOvarian cancer Differentially expressed between normal and patients 22086897
CancerPDF_ID3333 NANASerum6231.3MALDI-TOFOvarian cancer Differentially expressed between normal and patients 22086897
CancerPDF_ID3342 NANASerum6047.64MALDI-TOFNon-small cell lung cancer (NSCLC) Upregulated in cancer vs normal 22628229
CancerPDF_ID3366 NANASerum6387.9MALDI-TOFNon-small cell lung cancer (NSCLC) Downregulated in cancer vs normal 22628229
CancerPDF_ID3367 NANASerum6529.26MALDI-TOFNon-small cell lung cancer (NSCLC) Downregulated in cancer vs normal 22628229
CancerPDF_ID3368 NANASerum6937.21MALDI-TOFNon-small cell lung cancer (NSCLC) Downregulated in cancer vs normal 22628229
CancerPDF_ID3398 NANASerum6431.4MALDI-TOFNon-small cell lung cancer (NSCLC) Downregulated in cancer vs normal 22628229
CancerPDF_ID3399 NANASerum6629.53MALDI-TOFNon-small cell lung cancer (NSCLC) Downregulated in cancer vs normal 22628229
CancerPDF_ID8419 NANASerum6412.9MALDI-TOF"Breast cancer, Lung cancer, Rectal cancer" Frequency of peptide In lung cancer : 92.86% ; In Rectal cancer : 97.22% ; Breast cancer: 97%; In normal healthy individuals : 91% 23667664
CancerPDF_ID8444 NANASerum6626.75MALDI-TOF"Breast cancer, Lung cancer, Rectal cancer" Frequency of peptide In lung cancer : 98.57% ; In Rectal cancer : 97.22% ; Breast cancer: 98%; In normal healthy individuals : 55% 23667664
CancerPDF_ID8446 NANASerum6936.01MALDI-TOF"Breast cancer, Lung cancer, Rectal cancer" Frequency of peptide In lung cancer : 2.86% ; In Rectal cancer : 61.11% ; Breast cancer: 10%; In normal healthy individuals : 52% 23667664
CancerPDF_ID8453 NANASerum6526.74MALDI-TOF"Breast cancer, Lung cancer, Rectal cancer" Frequency of peptide in normal healthy : 45.2% 23667664
CancerPDF_ID8473 NANASerum6836.01MALDI-TOF"Breast cancer, Lung cancer, Rectal cancer" Frequency of peptide In lung cancer : 57.14% ; In Rectal cancer : 0% ; Breast cancer: 71%; In normal healthy individuals : 23.6% 23667664
CancerPDF_ID8618 TPDVSSALDKLKEFGNTLEDKARELISRIKQSELSAKMREWFSETFQKVKEKLKIDSApolipoprotein C-I precursorSerum6625.91MALDI-TOFBreast cancer Downregulated in cancer as compare to normal control with fold change of 1.5 26705257
CancerPDF_ID8620 ARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQApolipoprotein A-I precursorSerum6428.21MALDI-TOFBreast cancer Downregulated in cancer as compare to normal control with fold change of 1.7 26705257
CancerPDF_ID8626 NANASerum6634MS/MSEsophageal squamous cell carcinoma (ESCC) Diffrential expressed between cancer and normal 23586861
CancerPDF_ID8666 NANASerum6579.6MALDI-TOF"Hepatocellular carcinoma, Liver cirrhosis, Chronic hepatitis" significantly different from that of normal 23915185
CancerPDF_ID11038 NANASerum6433.36MALDI-TOFClear cell renal carcinoma "Downregulated in ccRCC, preoperative and post operative patients vs control" 25368985
CancerPDF_ID11109 NANAUrine6237.8MALDI-TOFClear cell renal carcinoma Upregulated in pT1b compared to pT1a patients 26482227
CancerPDF_ID11133 NANAUrine6261.4MALDI-TOFClear cell renal carcinoma Downregulated in ccRCC vs normal according to primary tumor Stage 26482227
CancerPDF_ID11134 NANAUrine6305.2MALDI-TOFClear cell renal carcinoma Downregulated in ccRCC vs normal according to primary tumor Stage 26482227
CancerPDF_ID12779 NANASerum6636.05MALDI-TOFHepatocellular carcinoma Downregulated in cancer vs Healthy 25910294
CancerPDF_ID14300 NANASerum6629.59Magnetic bead based weak cation exchange chromatography(MB-WCX)Gastric cancer NA 21739109
CancerPDF_ID14303 NANASerum6431.45Magnetic bead based weak cation exchange chromatography(MB-WCX)Gastric cancer NA 21739109
CancerPDF_ID14305 NANASerum6528.84Magnetic bead based weak cation exchange chromatography(MB-WCX)Gastric cancer NA 21739109
CancerPDF_ID14306 NANASerum6486.39Magnetic bead based weak cation exchange chromatography(MB-WCX)Gastric cancer NA 21739109
CancerPDF_ID14316 NANASerum6389.31Magnetic bead based weak cation exchange chromatography(MB-WCX)Gastric cancer NA 21739109
CancerPDF_ID14329 NANASerum6088.21Magnetic bead based weak cation exchange chromatography(MB-WCX)Gastric cancer NA 21739109
CancerPDF_ID14367 NANASerum6579.6MB-WCXHepatocellular carcinoma NA 23915185